Multiplicity Considerations in Clinical Trials | New England Journal of Medicine Skip to main content The New England Journal of Medicine homepage Advanced Search SEARCH …
L Lagae, J Sullivan, K Knupp, L Laux, T Polster… - The Lancet, 2019 - thelancet.com
Background Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy characterised by multiple types of frequent, disabling seizures …
JA Maertens, G Rahav, DG Lee, A Ponce-de-León… - The Lancet, 2021 - thelancet.com
Background Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have …
PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch …
Background Multiple primary outcomes may be specified in randomised controlled trials (RCTs). When analysing multiple outcomes it's important to control the family wise error rate …
Objective: Effective Skills to Empower Effective Men (ESTEEM) represents the first intervention to address the psychological pathways through which minority stress …
Adopting a unifying theme based on maximum statistics, Multiple Comparisons Using R describes the common underlying theory of multiple comparison procedures through …
Importance The optimal approach to the use of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiogenic shock is uncertain. Objective To determine whether …
J Chataway, F De Angelis, P Connick… - The Lancet …, 2020 - thelancet.com
Background Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research …